New Delhi, July 13 (RHC)-- India's Biocon Ltd has received regulatory approval for its drug Itolizumab to be used on coronavirus infected patients suffering from moderate to severe respiratory distress, the biopharmaceutical company said in a statement.
The drugs which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in India.
"The randomised control trial indicated that all patients treated with Itolizumab responded postiively and recovered," said Kiran Mazumdar-Shaw, the firm's executive chairperson.
